Multiple Myeloma in Relapse Recruiting Phase 3 Trials for Lenalidomide (DB00480)

IndicationStatusPhase
DBCOND0036092 (Multiple Myeloma in Relapse)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03952091TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple MyelomaTreatment